PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1

Biochemical and Biophysical Research Communications

Volumn 412, Issue 2, 2011, Pages 379-384

  Wang, Shuai ^a,b   Wang, Huibo ^b   Davis, Ben C ^b   Liang, Jiyong ^c   Cui, Rutao ^d   Chen, Sai Juan ^a   Xu, Zhi Xiang ^b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AKT; FOXO3A; PARP1 inhibitor; PHLPP1

Indexed keywords

3 AB; ANTINEOPLASTIC AGENT; GLYCOSYLTRANSFERASE INHIBITOR; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1 INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLECKSTRIN HOMOLOGY DOMAIN LEUCINE RICH REPEAT PROTEIN PHOSPHATASE 1; PROTEIN KINASE B; SERINE; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION;

BENZAMIDES; CELL LINE, TUMOR; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; NUCLEAR PROTEINS; PHENANTHRENES; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; UP-REGULATION;

EID: 80052035265     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.07.107     Document Type: Article

References (28)

1. Jeggo P.A. DNA repair: PARP - another guardian angel?. Curr. Biol. 1998, 8:R49-R51.
2. de Murcia G., de Murcia J.M. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem. Sci. 1994, 172-176.
3. Sandhu S.K., Yap T.A., de Bono J.S. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur. J. Cancer 2010, 46:9-20.
4. Tong Y., Bouska J.J., Ellis P.A., Johnson E.F., Leverson J., Liu X., Marcotte P.A., Olson A.M., Osterling D.J., Przytulinska M., Rodriguez L.E., Shi Y., Soni N., Stavropoulos J., Thomas S., Donawho C.K., Frost D.J., Luo Y., Giranda V.L., Penning T.D. Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents. J. Med. Chem. 2009, 52:6803-6813.
5. Penning T.D., Zhu G.D., Gandhi V.B., Gong J., Liu X., Shi Y., Klinghofer V., Johnson E.F., Donawho C.K., Frost D.J., Bontcheva-Diaz V., Bouska J.J., Osterling D.J., Olson A.M., Marsh K.C., Luo Y., Giranda V.L. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J. Med. Chem. 2009, 52:514-523.
6. Menear K.A., Adcock C., Boulter R., Cockcroft X.L., Copsey L., Cranston A., Dillon K.J., Drzewiecki J., Garman S., Gomez S., Javaid H., Kerrigan F., Knights C., Lau A., Loh V.M., Matthews I.T., Moore S., O'Connor M.J., Smith G.C., Martin N.M. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J. Med. Chem. 2008, 51:6581-6591.
7. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
8. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
9. Fong P.C., Yap T.A., Boss D.S., Carden C.P., Mergui-Roelvink M., Gourley C., De Greve J., Lubinski J., Shanley S., Messiou C., A'Hern R., Tutt A., Ashworth A., Stone J., Carmichael J., Schellens J.H., de Bono J.S., Kaye S.B. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 2010, 28:2512-2519.
10. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., Lu K., Schmutzler R.K., Matulonis U., Wickens M., Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
11. Turner N.C., Lord C.J., Iorns E., Brough R., Swift S., Elliott R., Rayter S., Tutt A.N., Ashworth A. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008, 27:1368-1377.
12. Lord C.J., McDonald S., Swift S., Turner N.C., Ashworth A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst). 2008, 7:2010-2019.
13. Xu Z.X., Ding T., Haridas V., Connolly F., Gutterman J.U. Avicin D, a plant triterpenoid, induces cell apoptosis by recruitment of Fas and downstream signaling molecules into lipid rafts. PLoS One 2009, 4:e8532.
14. Li W.J., Oh S.J. PARP inhibition prevents oxidative injury of bladder induced by acute urinary retention and subsequent emptying. Apoptosis 2011.
15. Chevanne M., Zampieri M., Caldini R., Rizzo A., Ciccarone F., Catizone A., D'Angelo C., Guastafierro T., Biroccio A., Reale A., Zupi G., Caiafa P. Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line. J. Cell Physiol. 2010, 222:401-410.
16. Wang S.J., Wang S.H., Song Z.F., Liu X.W., Wang R., Chi Z.F. Poly(ADP-ribose) polymerase inhibitor is neuroprotective in epileptic rat via apoptosis-inducing factor and Akt signaling. Neuroreport 2007, 18:1285-1289.
17. Potente M., Fisslthaler B., Busse R., Fleming I. 11,12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1. J. Biol. Chem. 2003, 278:29619-29625.
18. Kops G.J., Dansen T.B., Polderman P.E., Saarloos I., Wirtz K.W., Coffer P.J., Huang T.T., Bos J.L., Medema R.H., Burgering B.M. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002, 419:316-321.
19. Liu J., Weiss H.L., Rychahou P., Jackson L.N., Evers B.M., Gao T. Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene 2009, 28:994-1004.
20. Liang H., Tan A.R. Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. IDrugs 2010, 13:646-656.
21. Gao T., Furnari F., Newton A.C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 2005, 18:13-24.
22. Kops G.J., Medema R.H., Glassford J., Essers M.A., Dijkers P.F., Coffer P.J., Lam E.W., Burgering B.M. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol. Cell Biol. 2002, 22:2025-2036.
23. Schwab T.S., Madison B.B., Grauman A.R., Feldman E.L. Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells. Apoptosis 2005, 10:831-840.
24. Tsai W.B., Chung Y.M., Takahashi Y., Xu Z., Hu M.C. Functional interaction between FOXO3a and ATM regulates DNA damage response. Nat. Cell Biol. 2008, 460-467.
25. Yin L., Huang L., Kufe D. MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J. Biol. Chem. 2004, 279:45721-45727.
26. Chalhoub N., Baker S.J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 2009, 4:127-150.
27. Liu J., Stevens P.D., Gao T. mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J. Biol. Chem. 2011, 286:6510-6520.
28. Hirano I., Nakamura S., Yokota D., Ono T., Shigeno K., Fujisawa S., Shinjo K., Ohnishi K. Depletion of pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms. J. Biol. Chem. 2009, 284:22155-22165.